Integrating nanomedicine into clinical radiotherapy regimens

Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas Jr; Conroy Sun

doi:10.1016/j.addr.2019.07.002

Integrating nanomedicine into clinical radiotherapy regimens

Adv Drug Deliv Rev. 2019 Apr:144:35-56. doi: 10.1016/j.addr.2019.07.002. Epub 2019 Jul 4.

Authors

Allison N DuRoss¹, Megan J Neufeld¹, Shushan Rana², Charles R Thomas Jr², Conroy Sun³

Affiliations

¹ Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA.
² Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
³ Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA; Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: sunc@ohsu.edu.

Abstract

While the advancement of clinical radiotherapy was driven by technological innovations throughout the 20th century, continued improvement relies on rational combination therapies derived from biological insights. In this review, we highlight the importance of combination radiotherapy in the era of precision medicine. Specifically, we survey and summarize the areas of research where improved understanding in cancer biology will propel the field of radiotherapy forward by allowing integration of novel nanotechnology-based treatments.

Keywords: Cancer; Chemoradiotherapy; Dosing; Drug delivery; Multimodal therapy; Nanoparticles; Radiation therapy.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Combined Modality Therapy
Humans
Immunotherapy
Nanomedicine*
Neoplasms / drug therapy
Neoplasms / radiotherapy*

Grants and funding

R35 GM119839/GM/NIGMS NIH HHS/United States